Related Experiment Video

Updated: Dec 31, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.5K

The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity

Dan Lu1, Liang Liu1, Yizhe Sun1,2

  • 1Institute of Systems Biomedicine, Peking University Health Science Center, Beijing, China.

Nature Immunology
|January 15, 2020
PubMed

Insights

Dual specificity phosphatase 2 (DUSP2), also known as PAC1, acts as an immune checkpoint in T cells. Targeting PAC1 may enhance cancer immunotherapy by restoring T cell function.

Area of Science:

  • Immunology
  • Cancer Biology
  • Epigenetics

Background:

  • Cancer cells evade immune detection by inhibiting T cell effector functions.
  • Understanding T cell dysfunction is crucial for developing effective cancer immunotherapies.

Purpose of the Study:

  • To investigate the role of dual specificity phosphatase 2 (DUSP2/PAC1) as an immune checkpoint in T cell antitumor immunity.
  • To elucidate the mechanism by which PAC1 regulates T cell exhaustion in the tumor microenvironment.

Main Methods:

  • Analysis of PAC1 expression in tumor-infiltrating lymphocytes (TILs) and correlation with patient prognosis.
  • Investigating the functional consequences of PAC1 deletion in murine cancer models.
  • Elucidating the molecular pathway involving EGR1, reactive oxygen species, and the Mi-2β complex in PAC1-mediated T cell regulation.

Main Results:

  • PAC1 is upregulated in exhausted TILs and associated with poor cancer prognosis.
  • PAC1 deletion enhances anti-tumor immune responses and reduces cancer susceptibility in mice.
  • PAC1 induces T cell exhaustion by recruiting the Mi-2β complex for chromatin remodeling, a process initiated by EGR1 and reactive oxygen species.

Conclusions:

  • PAC1 functions as an epigenetic immune checkpoint regulating T cell exhaustion.
  • Targeting PAC1 presents a promising strategy for enhancing cancer immunotherapy efficacy.

More Related Videos

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

8.0K
Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

15.6K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K